RecruitingNot ApplicableNCT07550140

ETASCAN Project: ETAS Project 2

The Impact of Chronic Consumption of ETAS® for 12 Weeks on Cognitive, Affective, and Neural Outcomes: A Randomised Parallel Group Placebo-controlled Study


Sponsor

University of Reading

Enrollment

60 participants

Start Date

May 5, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.


Eligibility

Min Age: 60 YearsMax Age: 80 Years

Inclusion Criteria4

  • Aging between 60-80 years old
  • Having normal vision and hearing
  • Having a body mass index between 18.5 and 30
  • Having mild to moderate subjective cognitive complaints

Exclusion Criteria26

  • Smoking
  • Having food allergies
  • Following restrictive and/or unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes / No; Are you currently on a weight-reducing or other special diet? Yes/No If 'Yes', please give details.)
  • Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders
  • Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease
  • Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors
  • Currently consuming prebiotic or probiotic supplements
  • Continuous antibiotic use for > 3 days within 1 month prior to enrolment
  • Continuous use of weight-loss drug for > 1 month before screening
  • Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years
  • History of claustrophobia
  • Fitted with a pacemaker or artificial heart valve
  • Have active implants, such as cochlear, ocular, or penile implant
  • Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body
  • Drug infusion pump installed
  • Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction)
  • Have had any surgery that might have involved metal implants
  • Current or historical experience of epilepsy
  • Have stimulators for nerves, brain or bone installed
  • Have an intrauterine contraceptive device installed (IUD)
  • Wear transdermal patches containing metal
  • Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces
  • For scanning, would need to remove coloured contact lenses, nail polish and makeup.
  • Hearing aid wearer
  • Body piercings that you cannot or will not remove for the scanning session
  • Have tattoos or permanent makeup

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTETAS®

1500mg ETAS®

DIETARY_SUPPLEMENTPlacebo

Matched placebo capsule


Locations(1)

University of Reading, School of Psychology and Clinical Languages

Reading, Berkshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07550140


Related Trials